Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: a review of the literature
- PMID: 25317367
- PMCID: PMC4195639
- DOI: 10.4088/PCC.13r01600
Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: a review of the literature
Abstract
Objective: To raise awareness of attention-deficit/hyperactivity disorder (ADHD) as an underdiagnosed, undertreated, often comorbid, and debilitating condition in adults.
Data sources: PubMed was searched using combinations of keywords, including ADHD, adult, diagnosis, identify, prevalence, and comorbid, to find articles published between 1976 and 2013.
Study selection: In total, 99 articles were selected for inclusion on the basis of their relevance to the objective and importance to and representation of ADHD research, including international guidelines for adults with ADHD.
Results: In a large proportion of children with ADHD, symptoms persist into adulthood. However, although adults with ADHD often experience chaotic lifestyles, with impaired educational and vocational achievement and higher risks of substance abuse and imprisonment, many remain undiagnosed and/or untreated. ADHD is usually accompanied by other psychiatric comorbidities (such as major depressive disorder, anxiety disorder, and alcohol abuse). Indeed, adults with ADHD are more likely to present to a psychiatric clinic for treatment of their comorbid disorders than for ADHD, and their ADHD symptoms are often mistaken for those of their comorbidities. Untreated ADHD in adults with psychiatric comorbidities leads to poor clinical and functional outcomes for the patient even if comorbidities are treated. Effective treatment of adults' ADHD improves symptoms, emotional lability, and patient functioning, often leading to favorable outcomes (eg, safer driving, reduced criminality). A few medications have now been approved for use in adults with ADHD, while a multimodal approach involving psychotherapy has also shown promising results. Conclusions General psychiatrists should familiarize themselves with the symptoms of ADHD in adults in order to diagnose and manage ADHD and comorbidities appropriately in these patients.
Similar articles
-
Practical considerations for the evaluation and management of Attention Deficit Hyperactivity Disorder (ADHD) in adults.Encephale. 2020 Feb;46(1):30-40. doi: 10.1016/j.encep.2019.06.005. Epub 2019 Oct 11. Encephale. 2020. PMID: 31610922 Review.
-
[Awareness of adult attention-deficit/hyperactivity disorder (ADHD) in Greece].Psychiatriki. 2012 Jun;23 Suppl 1:60-5. Psychiatriki. 2012. PMID: 22796974 Review. Greek, Modern.
-
Diagnostic Dilemma of Differentiating Attention-Deficit/Hyperactivity Disorder (ADHD) From Mood Disorders and Other Common Psychiatric Illnesses in Substance Use Patient Population.Cureus. 2023 Apr 10;15(4):e37372. doi: 10.7759/cureus.37372. eCollection 2023 Apr. Cureus. 2023. PMID: 37041853 Free PMC article.
-
A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities.Neuropsychiatr Dis Treat. 2017 Feb 3;13:357-371. doi: 10.2147/NDT.S115707. eCollection 2017. Neuropsychiatr Dis Treat. 2017. PMID: 28223809 Free PMC article. Review.
-
Unrecognized attention-deficit/hyperactivity disorder in adults presenting with other psychiatric disorders.CNS Spectr. 2008 Nov;13(11):977-84. doi: 10.1017/s1092852900014036. CNS Spectr. 2008. PMID: 19037178
Cited by
-
Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together.Transl Psychiatry. 2024 Mar 19;14(1):151. doi: 10.1038/s41398-024-02859-2. Transl Psychiatry. 2024. PMID: 38504095
-
Prenatal exposure to polybrominated diphenyl ethers and inattention/hyperactivity symptoms in mid to late adolescents.Front Epidemiol. 2023 Jun 21;3:1061234. doi: 10.3389/fepid.2023.1061234. eCollection 2023. Front Epidemiol. 2023. PMID: 38455925 Free PMC article.
-
Protocol of a monocentric, double-blind, randomized, superiority, controlled trial evaluating the effect of in-prison OROS-methylphenidate vs. placebo treatment in detained people with attention-deficit hyperactivity disorder (BATIR).Trials. 2024 Jan 4;25(1):23. doi: 10.1186/s13063-023-07827-7. Trials. 2024. PMID: 38178233 Free PMC article.
-
QbTest for Monitoring Medication Treatment Response in ADHD: A Systematic Review.Clin Pract Epidemiol Ment Health. 2023 Nov 1;19:e17450179276630. doi: 10.2174/0117450179276630231030093814. eCollection 2023. Clin Pract Epidemiol Ment Health. 2023. PMID: 38164455 Free PMC article.
-
Risk factors associated with newly diagnosed attention-deficit/hyperactivity disorder in adults: a retrospective case-control study.BMC Psychiatry. 2023 Nov 23;23(1):870. doi: 10.1186/s12888-023-05359-7. BMC Psychiatry. 2023. PMID: 37996794 Free PMC article.
References
-
- Wood DR, Reimherr FW, Wender PH, et al. Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Arch Gen Psychiatry. 1976;33(12):1453–1460. - PubMed
-
- Hill JC, Schoener EP. Age-dependent decline of attention-deficit/hyperactivity disorder. Am J Psychiatry. 1996;153(9):1143–1146. - PubMed
-
- Turgay A, Goodman DW, Asherson P, et al. ADHD Transition Phase Model Working Group. Lifespan persistence of ADHD: the life transition model and its application. J Clin Psychiatry. 2012;73(2):192–201. - PubMed
-
- Trollor JN. Attention-deficit/hyperactivity disorder in adults: conceptual and clinical issues. Med J Aust. 1999;171(8):421–425. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources